Posso ottenerlo?
Sì, se un medico ritiene che sia adatto a Lei. Caverject è autorizzato nell’UE e può essere prescritto dopo una valutazione medica.
CaverjectSolo su prescrizione
Consulto medico online per Caverject.
Un medico autorizzato dall'UE esamina il Suo caso e, se idoneo, rilascia una prescrizione elettronica valida in qualsiasi farmacia dell'UE ai sensi della direttiva 2011/24/UE.
- A non-PDE5 route
- Direct, local action
- An option when oral PDE5s don't work or aren't allowed
Inizia consultoInizia consulto · 35 €
Rimborso completo se una valutazione non viene approvata · Il farmaco, se prescritto, viene dispensato e pagato separatamente in farmacia.
IN PAROLE SEMPLICI
Cos’è Caverject e come ottenere un trattamento
Alprostadil è una copia della prostaglandina E1, una sostanza che il corpo produce naturalmente e che dilata i vasi sanguigni. A differenza delle compresse, viene applicato direttamente sul pene: come crema sulla punta, come iniezione sul lato del corpo del pene o come piccolo pellet inserito nell’uretra. In questo modo agisce direttamente sui vasi sanguigni. È autorizzato nei Paesi dell’UE per la disfunzione erettile dal 1994 come iniezione e dal 2014 come crema. Poiché agisce localmente, anche i principali effetti indesiderati sono locali: bruciore, dolore o arrossamento nel punto di applicazione e, raramente, un’erezione che dura troppo a lungo e richiede assistenza medica urgente.
Caverject è autorizzato per l’uso nell’UE dal 29 novembre 1994. Un medico abilitato può quindi prescriverlo quando è clinicamente adatto a Lei.
Cosa posso prendere al suo posto?
I nostri medici esaminano ogni opzione per Salute sessuale e consigliano quella più adatta alla Sua storia clinica e ai Suoi obiettivi.
Veda tutte le opzioni per Salute sessualeCosa mostrano gli studi?
Tutti gli studi su Caverject sono elencati qui sotto con il numero di partecipanti e l’indicazione se i risultati sono stati sottoposti a revisione paritaria o provengono da un annuncio dell’azienda.
Vada agli studiEVIDENZE VERIFICATE
Caverject: guida alle evidenze e alla regolamentazione.
CHE COS’È
Come agisce
Alprostadil is a man-made copy of a natural body chemical (prostaglandin E1) that is applied to or injected into the penis, where it widens the blood vessels directly so blood flows in.
FASE DI SVILUPPO
Medicinale autorizzato nell’UE
Registro degli studi4 studi registrati
Ogni identificativo NCT rimanda al record ClinicalTrials.gov. Una comunicazione dei risultati non equivale a una pubblicazione sottoposta a revisione paritaria.
| STUDIO / NCT | POPOLAZIONE | PARTECIPANTI | STATO | RISULTATO / COMPLETAMENTO |
|---|---|---|---|---|
| Integrated analysis of two multicentre, double-blind, parallel-group topical-cream studies | Men with an IIEF erectile function domain score of 25 or less, including men with diabetes and men taking organic nitrates | 1,732 | Con risultati | 2006-08-01 |
| Alprostadil Study Group — intracavernosal dose-response study | Men with erectile dysfunction of vasculogenic, neurogenic, psychogenic and mixed causes | 296 | Con risultati | 1996-04-04 |
| Alprostadil Study Group — six-month intracavernosal self-injection study | Men with erectile dysfunction of mixed causes | 683 | Con risultati | 1996-04-04 |
| MUSE Study Group — transurethral alprostadil, double-blind placebo-controlled trial | Men aged 27-88 with chronic erectile dysfunction from various organic causes | 1,511 | Con risultati | 1997-01-02 |
Che cosa hanno riportato gli studi
I risultati sono separati per fonte e grado di evidenza, così i dati scientifici non vengono confusi con gli annunci del produttore.
Revisione paritaria
Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 2006;68(2):386-391. doi:10.1016/j.urology.2006.02.027 (PMID 16904458)| DOSE O GRUPPO | VARIAZIONE MEDIA DEL PESO | SETTIMANE |
|---|---|---|
| 100 microgram cream (n=434) | IIEF erectile function domain change from baseline +1.6 points vs -0.7 on placebo (p<0.001) | 12 |
| 200 microgram cream (n=430) | IIEF erectile function domain change from baseline +2.5 points vs -0.7 on placebo (p<0.001) | 12 |
| 300 microgram cream (n=434) | IIEF erectile function domain change from baseline +2.4 points vs -0.7 on placebo (p<0.001) | 12 |
The IIEF changes are small in absolute terms and the authors describe the SEP2 and SEP3 improvements as slight though statistically significant; the studies ran for 12 weeks and cover the topical cream only, not the injected or intraurethral forms.
Fonti
Ultima revisione 2026-07-27
- AEMPS CIMA — Caverject 20 microgramos (alprostadil, intracavernosal injection), reg. 60535, first authorised in Spain 29 November 1994, indicated for erectile dysfunction
- AEMPS CIMA — Virirec 3 mg/g crema (alprostadil topical), reg. 78357, first authorised April 2014; the same cream was approved via the EU decentralised procedure as Vitaros in 2013
- Urology 2006 — Integrated analysis of alprostadil topical cream in 1,732 patients (PMID 16904458)
- N Engl J Med 1996 — Efficacy and safety of intracavernosal alprostadil (PMID 8596569)
- N Engl J Med 1997 — Treatment of men with erectile dysfunction with transurethral alprostadil, MUSE Study Group (PMID 8970933)
SEGNALI DI SICUREZZA IDENTIFICATI
Che cosa è stato segnalato con Caverject.
Application-site burning, penile pain and redness (cream)
Penile burning, penile pain, penile erythema, genital pain and genital discomfort are all listed as common in the EU product information for alprostadil 3 mg/g cream. In the clinical trial the withdrawal rate was 30% in the 300 microgram group compared with 20% in the 200 microgram group.
Injection-site pain (intracavernosal)
Penile pain is listed as very common in the EU product information for alprostadil injection. In the six-month self-injection study, usually mild penile pain occurred in 50% of men at some time but after only 11% of injections.
Prolonged erection and priapism (intracavernosal)
In the EU product information for alprostadil injection, a prolonged erection lasting 4 to 6 hours developed in 4% of patients and priapism (a painful erection lasting more than 6 hours) in 0.4%. In the six-month self-injection study, prolonged erections occurred in 5% of men and priapism in 1%.
Prolonged erection and priapism (cream)
Listed as uncommon in the EU product information for alprostadil cream. Priapism was seen in 1 patient (0.06%) across the two 3-month studies and in 5 patients (0.4%) in the study lasting more than 6 months. An erection lasting more than 4 hours needs immediate medical help, because untreated priapism can permanently damage erectile tissue.
Penile fibrosis (intracavernosal)
Penile fibrosis, including angulation, fibrotic nodules and Peyronie's disease, was reported in 3% of clinical-trial patients in the EU product information for alprostadil injection, rising to about 8% in a self-administration study of up to 18 months. Injection-site haematoma was reported by 3% and bruising by 2%.
Dizziness and fainting
In the phase 3 cream studies, symptomatic low blood pressure (dizziness) and fainting occurred in 0.4%, 0.4% and 0.5% of patients on the 100, 200 and 300 microgram doses. Patients are advised not to drive or do hazardous tasks until they know how they react.
Effects on a female partner
Vulvovaginal burning and vaginitis are listed as common reactions in female partners in the EU product information for alprostadil cream.
Penile pain (intraurethral)
In the transurethral pivotal trial, mild penile pain was the most common side effect, occurring after 10.8% of treatments; in-clinic low blood pressure occurred in 3.3% of men, and no man had priapism or penile fibrosis.
FormaCrema uretrale o iniezione
FrequenzaAl bisogno
RisultatiDirect local action
Quanto paghi a Hi-Doctor35 € una tantum
IN 60 SECONDI
Caverject in sintesi
- A prostaglandin E1 medicine that widens the blood vessels inside the penis
- Adult men whose erectile dysfunction is unsuited to, or not helped by, oral tablets
- Given as a cream at the tip of the penis, a urethral pellet, or an injection
- An erection lasting 4 hours or more is priapism, and it is a medical emergency
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
DATI DEL PRODOTTO
Caverject in sintesi
- TITOLARE DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO
- Pfizer, S.L.
- CONFEZIONI
- 10 micrograms powder and solvent for solution for injection · 20 micrograms powder and solvent for solution for injection
Sul trattamento
Che cos'è Caverject?
Caverject contiene il principio attivo alprostadil.
Principio attivo: Alprostadil · Dosaggi: Cream 3 mg/g on demand
Alprostadil is a prostaglandin E1 that directly dilates the blood vessels of the penis. It's considered when oral PDE5 inhibitors are ineffective or contraindicated.
It's administered as a urethral cream or an intracavernous injection, under medical instruction — each route has its own efficacy and tolerability profile. Correct technique matters, and the doctor explains the protocol and the warning signs.
COME AGISCE
Che cosa fa Caverject nel tuo corpo
Rather than blocking an enzyme, alprostadil acts directly on the penile blood vessels, dilating them locally — no PDE5 pathway involved, so it can work where oral options don't.
A copy of prostaglandin E1
Alprostadil is chemically identical to prostaglandin E1, a signalling substance the body already makes. It is not swallowed. It is placed into or onto the penis itself, so it acts on the erectile tissue at the site rather than circulating through the whole body first.
Cavernosal muscle relaxes
The drug relaxes the smooth muscle of the corpora cavernosa, the two spongy cylinders that run the length of the penis, and widens the cavernosal arteries feeding them. Blood flow into the erectile tissue rises, and that increase in flow is what produces rigidity.
It does not need arousal
Because it acts on the tissue directly, alprostadil does not depend on the nitric oxide signal that sexual stimulation produces. In clinic testing it created erections on its own. That is the core difference from tablets, and it is also why an erection can outlast the encounter.
Come aiuta
How it helps.
A different pathway
Works directly on the blood vessels — not through the PDE5 enzyme.
Local application
Applied where it acts, shortly before intercourse.
Guided by your doctor
Administration technique and warning signs are explained before you start.
Cosa aspettarsi
How to use it.
Prescribed with clear administration instructions. Your doctor explains the protocol, and follow-up happens through your account chat.
- Prescribed with clear administration instructions
- Applied shortly before intercourse
- Correct technique matters — your doctor explains it
- Follow-up and questions through your account chat
Forms your doctor can prescribe
- Urethral cream3 mg/g — on demand
Il Suo piano è personale
Questi passaggi sono solo indicativi. Il medico adatta il piano alla Sua risposta e tolleranza — e può scrivergli in qualsiasi momento.
NELLA VITA QUOTIDIANA
Usare Caverject nella vita quotidiana
Get shown the technique first
Every form of alprostadil has to be demonstrated by a medical professional before you use it yourself. For the injection and the urethral pellet the first doses are given or supervised in a clinic, not at home, and that step cannot be skipped.
Empty your bladder first
Urinate before using the cream or the pellet. A moist urethra helps the medicine dissolve and spread. Do not urinate straight after the cream, because the dose can be washed out before it has had time to work.
Cream sits at the opening
Roll the single-dose container between your hands to warm it, hold the penis upright and squeeze the tip to widen the opening. Place the container at the opening without inserting it, push all the cream in, then hold the penis upright for about 30 seconds.
Pellet needs a stretch and roll
For the urethral pellet, stretch the penis upward to its full length, insert the applicator, press the button and withdraw it. Then roll the penis between your hands for at least 10 seconds so the medicine coats the urethral wall.
Stand or walk for ten minutes
After the pellet, sit or preferably stand or walk for about 10 minutes while the erection develops. An erection usually appears 5 to 10 minutes after the pellet and lasts roughly 30 to 60 minutes. The cream works in 5 to 30 minutes.
Injections rotate side and site
The injection goes into the upper side of the penis, along the third nearest the body, avoiding visible veins. Change both the side and the exact spot each time. Never straighten or reuse a bent needle, because needles can break.
Use a condom if pregnancy is possible
A condom is required if your partner is pregnant or could become pregnant, and it also reduces vaginal irritation, which is a reported reaction. Only latex condoms have been tested with the cream. Alprostadil is not a contraceptive and does not prevent infection.
Respect the frequency limits
The cream is used at most 2 to 3 times a week and once in 24 hours. Injections are at most once a day and three times a week. The pellet is at most 2 doses in 24 hours and 7 in 7 days.
Sicurezza prima di tutto
La sicurezza, per intero.
Caverject è un farmaco efficace — e, come ogni farmaco, comporta dei rischi. Il medico verifica tutto questo prima di prescrivere. Ecco il quadro onesto, non solo una rassicurazione.
Effetti indesiderati, per frequenza
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- An erection lasts 4 hours or more, which is priapism and a medical emergency that must not be left more than 6 hours
- Penile pain will not settle, or you notice a new bend, lump or hard patch in the penis
- You faint, feel close to fainting, or go dizzy with a sudden drop in blood pressure after a dose
- You get chest pain, or sudden weakness, numbness or trouble speaking
- Bleeding from the urethra will not stop, or there is blood in your urine
- Hives, a spreading rash or swelling appear, which can signal an allergic reaction
- A needle breaks and a fragment stays in the penis, which has needed surgical removal
Very common
very common (≥1/10)
more than 1 in 10 people
- Penile pain after intracavernosal injection, reported at least once by 30% of men and after 11% of injections
- Penile pain after the urethral pellet, in most cases rated mild or moderate
- Burning in the urethra after the urethral pellet
Common
common (≥1/100 to <1/10)
somewhere between 1 in 100 and 1 in 10 people
- Burning, tingling, throbbing or numbness in the penis, with the cream
- Redness, swelling, itching or general discomfort of the penis or genitals, with the cream
- Urethral pain with the cream, or minor urethral bleeding with the pellet
- An erection stronger or longer than expected, listed for all three forms
- Peyronie's disease, penile fibrosis, angulation or fibrotic nodules, with the injection and the pellet
- Bruising or a collection of blood at the injection site
- Headache, dizziness, symptomatic low blood pressure and muscle spasms, with the pellet
- Vaginal burning or itching in the partner, reported by about 6% of partners in the pellet studies
- Skin rash, with the cream
- Balanitis, inflammation of the head of the penis, with the cream
Uncommon
uncommon (≥1/1,000 to <1/100)
somewhere between 1 in 1,000 and 1 in 100 people
- Prolonged erection or priapism, listed at this frequency for all three forms
- Dizziness, fainting or a fall in blood pressure, listed for all three forms
- Painful erection, excessive rigidity, or loss of sensation in the penis
- Narrowing of the urethra, or inflammation of the urinary tract, with the cream
- Painful or frequent urination, urgency, blood in the urine or urethral bleeding
- Testicular or scrotal pain, swelling, redness or a lump, and pelvic or perineal pain
- Phimosis, ejaculation problems, or erectile dysfunction reported as a reaction
- Nausea, dry mouth, sweating, itching, rash, redness or a faster heartbeat
- Itching of the vulva or vagina in the partner, with the cream
- Widened pupils, extra heartbeats, a raised blood creatinine reading, or feeling weak
Rare
rare (≥1/10,000 to <1/1,000)
somewhere between 1 in 10,000 and 1 in 1,000 people
- Urinary tract infection, listed at this frequency for the urethral pellet
- Penile fibrosis, listed at this frequency for the urethral pellet
Very rare
very rare (<1/10,000)
fewer than 1 in 10,000 people
- Hives, known medically as urticaria, listed at this frequency for the urethral pellet
Frequency not known
not known (cannot be estimated from the available data)
reported after launch, but too rarely counted to put a number on
- Stroke, recorded in the injection product information as cerebrovascular accident
- Reduced blood supply to the heart muscle, recorded as myocardial ischaemia
Disfunzione erettile negli uomini adulti, come alternativa locale alle compresse.
- Applichi la dose monouso sull'apertura in punta al pene 5–30 minuti prima del rapporto, seguendo la tecnica del foglietto illustrativo.
- L'effetto dura circa 1–2 ore.
- Massimo una dose ogni 24 ore, e non più di 2–3 dosi a settimana.
- Si lavi le mani dopo l'applicazione.
CHI NON DEVE ASSUMERLO E CHI RICHIEDE CAUTELA
- You have sickle-cell disease or sickle-cell trait, multiple myeloma or leukaemia, all of which predispose to priapism
- You have another condition predisposing to priapism, such as thrombocythaemia, polycythaemia, a tendency to venous thrombosis, a hyperviscosity syndrome, or past recurrent priapism
- You have a penile implant
- Your penis is anatomically deformed, including angulation, curvature, cavernosal fibrosis, Peyronie's disease or severe hypospadias
- You have urethritis or balanitis, or for the pellet a narrowing of the lower urethra
- You are allergic to alprostadil or to any other ingredient in the product
- A doctor has advised that sexual activity is inadvisable, for example with severe heart disease or unstable heart or circulation problems
- You have orthostatic hypotension, or a history of heart attack or fainting, which rule out the cream
- Your partner is pregnant or could become pregnant and a condom will not be used
- You are already using another erectile dysfunction treatment, including a PDE5 inhibitor tablet or another injected agent
Quando cercare assistenza urgente
In caso di sintomi gravi, improvvisi o inattesi, chiami il numero di emergenza locale o si rechi al pronto soccorso più vicino. Poi informi il medico tramite la chat del Suo account.
Farmaci e sostanze che interagiscono
| FARMACO O SOSTANZA | COSA PUÒ ACCADERE | COSA FA IL MEDICO |
|---|---|---|
| PDE5 inhibitor tablets (sildenafil, tadalafil, vardenafil) | Never studied together; both act on blood vessels, so cardiovascular risk could add up | Not used together; the prescriber keeps you on one treatment at a time |
| Other injected erection agents (papaverine, phentolamine, thymoxamine) | Raises the risk of priapism, a painful prolonged abnormal erection | Not combined; alprostadil is prescribed on its own |
| Blood pressure medicines and other vasodilators | Blood pressure can fall further, and the risk is higher in older men | Prescribed with caution, with clear warning about dizziness and fainting |
| Anticoagulants and antiplatelet drugs (warfarin, heparin) | More bleeding after an injection, and more urethral bleeding or blood in the urine | Prescriber weighs the bleeding risk and may rule out the injected route |
| Sympathomimetics, decongestants and appetite suppressants | May reduce the effect of alprostadil, so a working dose can seem to fail | Prescriber reviews the full medicine list before changing any dose |
| Latex condoms | Only latex has been tested with the cream; other materials may be damaged by it | Use a latex condom, which is required anyway if a partner could be pregnant |
Fai valutare il tuo caso da un medicoÈ esattamente ciò che il medico verifica prima di prescrivere qualsiasi cosa.
Leggi il riepilogo completo sulla sicurezza di CaverjectEVIDENZE
Che cosa hanno rilevato gli studi clinici
In the two New England Journal of Medicine programmes that registered these products, the MUSE Study Group trial of the urethral pellet and the Alprostadil Study Group trials of intracavernosal injection, both routes produced erections firm enough for intercourse in most men who had first responded to a supervised test dose.
1,511 men aged 27 to 88 with chronic erectile dysfunction of organic cause · single clinic visit, up to four test doses
Transurethral alprostadil tested at 125, 250, 500 and 1000 micrograms
Fonte: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)961 in-clinic responders who reported at least one home treatment · 3 months of home use
Transurethral alprostadil versus placebo, p<0.001; on average 7 of 10 doses were followed by intercourse
Fonte: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)683 men in a self-injection study of intracavernosal alprostadil · 6 months
Patients and partners rated the activity satisfactory after 87% and 86% of injections
Fonte: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group)the same 1,511-man transurethral alprostadil programme · clinic testing plus 3 months at home
The most common side effect; no man in that study had priapism or penile fibrosis
Fonte: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)men across three multicentre intracavernosal alprostadil studies · up to 6 months of self-injection
Alongside prolonged erection in 5% and penile pain in 50% of men, after 11% of injections
Fonte: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group)These are group averages from trials, not a forecast for any one person. Both routes were screened in clinic first, and the home figures describe only the men who had already responded to that supervised test dose, so they read better than the result an unselected group would get. The European Association of Urology also records that 41% to 68% of men stop intracavernous injections, most within the first two to three months, and that only about 30% stay on the urethral pellet long term, which is a fair reminder that tolerating a treatment matters as much as its measured efficacy.
ALTERNATIVE
Alprostadil vs the oral tablets usually tried first
| FARMACO | COME SI ASSUME | OGNI QUANTO | INTERVALLO DI DOSE ABITUALE | INDICAZIONE AUTORIZZATA NELL'UE | EVIDENZA PRINCIPALE |
|---|---|---|---|---|---|
| Sildenafil | Compressa per via orale | Al bisogno, massimo una volta al giorno | 25–100 mg | Erectile dysfunction in adult men; sexual stimulation is required | Dose-response study: improved erections 56%, 77%, 84% vs 25% placebo |
| Tadalafil | Compressa per via orale | Al bisogno, o 5 mg una volta al giorno | 2.5–20 mg | Erectile dysfunction in adult males; sexual stimulation is required | Dose-response study: improved erections 67% and 81% vs 35% placebo |
| Vardenafil | Compressa per via orale | Al bisogno, massimo una volta al giorno | 5–20 mg | Erectile dysfunction in adult men; sexual stimulation is required | Dose-response study: improved erections 66%, 76%, 80% vs 30% placebo |
Non sai quale sia adatto al tuo caso? Il medico esamina la tua storia clinica e te lo dice.
Inizia consulto · 35 €ACCESSO E COSTI
Come ottenere Caverject e quanto costa
Alprostadil is prescription-only in every EU country and no form of it is sold over the counter anywhere. Which form you can actually obtain varies a lot, so each row was read off that country's own medicines register rather than inferred from the EU-wide picture. The registers do not all publish the same thing: Spain, Portugal and Belgium record a marketing status per product, so those rows describe what is genuinely on sale, while Germany and Austria publish only whether an authorisation is currently valid, so their rows describe which forms are registered rather than which a pharmacy is stocking this week. Poland registers no alprostadil product for erectile dysfunction at all. The linked database is the current authority in every case.
Quanto paghi a Hi-Doctor
35 € una tantum
Risponda ad alcune domande e un medico autorizzato dall'UE esaminerà il Suo caso in meno di 2 ore in media. Rimborso completo se non fa per Lei.
Quanto addebita la farmacia
Hi-Doctor non vende, non detiene e non dispensa farmaci e non ne stabilisce il prezzo. Il farmaco si paga separatamente in farmacia e l'importo dipende dal paese, dalla confezione, dalla disponibilità di un generico e dalla rimborsabilità. La banca dati ufficiale collegata nella tabella pubblica il prezzo autorizzato in vigore.
| PAESE | REGIME DI FORNITURA | RIMBORSATO DAL SISTEMA SANITARIO? | FONTE UFFICIALE |
|---|---|---|---|
| Spagna | Soggetto a prescrizione medica; l'iniezione ha una restrizione diagnostica ospedaliera | See national criteria | AEMPS CIMA |
Mostra gli altri paesi
| Germania | Soggetto a prescrizione medica; iniezione, bastoncino uretrale e crema hanno tutti un'autorizzazione valida | Excluded from statutory health insurance | PharmNet.Bund AMIce |
|---|---|---|---|
| Francia | Soggetto a prescrizione medica; le iniezioni sono liste I | Restricted — only for the organic causes listed in the official decision | Base de données publique des médicaments |
| Italia | Soggetto a prescrizione medica; è necessario un piano terapeutico specialistico per la copertura | Restricted — AIFA Nota 75, intracavernosal injection only | AIFA Medicinali |
| Paesi Bassi | Medicinale soggetto a prescrizione medica | See national criteria | CBG-MEB Geneesmiddeleninformatiebank |
| Portogallo | Soggetto a prescrizione medica (MSRM); l'iniezione e la crema hanno ciascuna almeno una presentazione commercializzata | See national criteria | INFARMED Infomed |
| Belgio | Soggetto a prescrizione medica; l'iniezione e la crema sono commercializzate, la cartuccia a doppia camera no | See national criteria | FAGG-AFMPS medicines database |
| Irlanda | Medicinale soggetto a prescrizione medica | See national criteria | HPRA Find a Medicine |
| Austria | Soggetto a prescrizione medica (Rp); il bastoncino uretrale risulta commercializzato, l'iniezione e la crema autorizzate | See national criteria | BASG Medikamente Info Austria |
| Polonia | Non commercializzato | — | Rejestr Produktów Leczniczych |
PREZZI
Paghi solo se il trattamento è approvato.
35 € per una consultazione di salute sessuale. Un unico pagamento, senza addebiti ricorrenti.
Salute sessuale
UNA TANTUM
35 € una tantum
Un consulto, un medico, una decisione.
Niente viene mai archiviato pubblicamente
Inizia consulto
Rimborso completo se una valutazione non viene approvata
COSA È INCLUSO
- Consulto valutato da un medico abilitato nell'UE
- Ricetta elettronica in caso di approvazione
- Rimborso completo in caso di rifiuto
Rimborso completo se una valutazione non viene approvata
Se una valutazione non viene approvata, rimborsiamo integralmente i 35 € della consulenza.
Nota: Il farmaco, se prescritto dal medico, viene pagato separatamente in farmacia al prezzo stabilito. Hi-Doctor non vende farmaci.
COME DECIDE IL MEDICO
Il tuo caso lo valuta un medico abilitato, non un algoritmo
Un medico abilitato nell'UE legge il tuo questionario e risponde in meno di 2 ore in media.
Se il medico decide che non è sicuro prescrivere, il costo della consulenza viene rimborsato per intero.
Il follow-up avviene nella chat privata del tuo account, nel rispetto del GDPR. Niente WhatsApp, niente SMS.
DOMANDE FREQUENTI
Domande su Caverject.
ALTRI TRATTAMENTI SALUTE SESSUALE
Esplora i trattamenti correlati.
FONTI
Da dove provengono queste informazioni
- 01
Vitaros 3 mg/g cream: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 02
Caverject Dual Chamber 20 micrograms: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 03
MUSE 500 microgramos bastoncillo uretral: Ficha Técnica — AEMPS, Spain, 2016
- 04
Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group) — New England Journal of Medicine 336(1):1-7, 1997
- 05
Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group) — New England Journal of Medicine 334(14):873-7, 1996
- 06
EAU Guidelines on Sexual and Reproductive Health, limited update March 2025 — European Association of Urology, 2025
- 07
Alprostadil: authorised medicines register (Caverject, Virirec and alprostadil cream marketed; MUSE authorised but not marketed) — AEMPS CIMA, Spain, 2026
- 08
Alprostadil: Vitaros 300 microgrammes cream and Edex 10/20 microgrammes marketed, liste I, restricted reimbursement — Base de données publique des médicaments, France, 2026
- 09
Alprostadil products authorised in Ireland: Caverject 10 and 20 micrograms, Vitaros 3 mg/g cream — medicines.ie, Irish medicines compendium, 2026
- 10
Register of medicinal products: no ATC G04BE01 alprostadil product registered for erectile dysfunction — Rejestr Produktów Leczniczych, Poland, 2026
- 11
Nota 75: reimbursement of alprostadil by intracavernosal injection limited to defined neurological criteria — AIFA, Gazzetta Ufficiale della Repubblica Italiana n. 7, 2017
- 12
§ 34 SGB V: medicines predominantly for erectile dysfunction excluded from statutory health insurance — Bundesministerium der Justiz, Germany, 2026
- 13
Regeling zorgverzekering: MUSE urethral stick 125 to 1000 micrograms listed on the Dutch medicines annex — Wetten.overheid.nl, Netherlands, 2026
- 14
Viagra (sildenafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2025
- 15
Cialis (tadalafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2025
- 16
Levitra (vardenafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2024
- 17
Alprostadil, human medicines with a currently valid German authorisation: Caverject and Caverject Impuls 10 and 20 micrograms (Pfizer Pharma GmbH plus parallel importers), Muse 500 and 1000 micrograms (Viatris Healthcare GmbH), Vitaros 300 micrograms/100 mg cream (The Simple Pharma Company Limited). The register publishes marketability, not whether a product is currently distributed. — BfArM AMIce, public part, via PharmNet.Bund, Germany, 2026
- 18
Alprostadilo: Caverject 0,01 and 0,02 mg/ml (Laboratórios Pfizer, Lda.) and Vitaros cream 0,3 mg/100 mg (Recordati Ireland Ltd.), each authorised with at least one marketed presentation — INFARMED Infomed, Portugal, 2026
- 19
Alprostadil: Caverject 10 and 20 micrograms and Vytaros 3 mg/g cream recorded as commercialised; Caverject Impuls 10 and 20 micrograms recorded as not commercialised — FAGG-AFMPS medicines database, Belgium, 2026
- 20
Alprostadil, ATC G04BE01: Muse 250, 500 and 1000 micrograms recorded as marketed; Caverject, Caverject Dual and Vitaros 3 mg/g cream authorised, with no marketing status published — BASG Medikamente Info Austria, Arzneispezialitätenregister, 2026
Revisionato dal team medico di Hi-Doctor · Ultima revisione 2026-07-27 · Prossima revisione prevista il 2027-07-27
Questa pagina contiene informazioni su un farmaco: non è una raccomandazione ad assumerlo né sostituisce una visita medica. Solo un medico abilitato che abbia esaminato la tua storia clinica può stabilire se un trattamento è adatto a te.
Scopra se fa per Lei
Verifichi se Caverject è appropriato per Lei.
Risponda ad alcune domande e un medico autorizzato dall'UE esaminerà il Suo caso in meno di 2 ore in media. Rimborso completo se non fa per Lei.